Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics Statistics
Share Statistics
Lyra Therapeutics has 65.88M shares outstanding. The number of shares has increased by 8.06% in one year.
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | 8.06% |
| Shares Change (QoQ) | 0.65% |
| Owned by Institutions (%) | 41.07% |
| Shares Floating | 54.86M |
| Failed to Deliver (FTD) Shares | 7.43K |
| FTD / Avg. Volume | 0.73% |
Short Selling Information
The latest short interest is 2.13M, so 3.26% of the outstanding shares have been sold short.
| Short Interest | 2.13M |
| Short % of Shares Out | 3.26% |
| Short % of Float | 3.98% |
| Short Ratio (days to cover) | 1.09 |
Valuation Ratios
The PE ratio is -0.14 and the forward PE ratio is -0.19. Lyra Therapeutics's PEG ratio is -0.01.
| PE Ratio | -0.14 |
| Forward PE | -0.19 |
| PS Ratio | 8.76 |
| Forward PS | 0.1 |
| PB Ratio | 1.16 |
| P/FCF Ratio | -0.19 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lyra Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 2.97.
| Current Ratio | 3.41 |
| Quick Ratio | 3.41 |
| Debt / Equity | 2.97 |
| Debt / EBITDA | -0.57 |
| Debt / FCF | -0.48 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $51.13K |
| Profits Per Employee | $-3.11M |
| Employee Count | 30 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 39K |
| Effective Tax Rate | -0.04% |
Stock Price Statistics
The stock price has increased by -97.86% in the last 52 weeks. The beta is -0.18, so Lyra Therapeutics's price volatility has been lower than the market average.
| Beta | -0.18 |
| 52-Week Price Change | -97.86% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 22.6 |
| Average Volume (20 Days) | 1.01M |
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -1.43.
| Revenue | 1.53M |
| Gross Profit | 1.53M |
| Operating Income | -96.35M |
| Net Income | -93.44M |
| EBITDA | -60.26M |
| EBIT | -60.73M |
| Earnings Per Share (EPS) | -1.43 |
Balance Sheet
The company has 40.58M in cash and 34.38M in debt, giving a net cash position of 6.2M.
| Cash & Cash Equivalents | 40.58M |
| Total Debt | 34.38M |
| Net Cash | 6.2M |
| Retained Earnings | -404.79M |
| Total Assets | 66.35M |
| Working Capital | 30.39M |
Cash Flow
In the last 12 months, operating cash flow was -70.01M and capital expenditures -2.34M, giving a free cash flow of -72.35M.
| Operating Cash Flow | -70.01M |
| Capital Expenditures | -2.34M |
| Free Cash Flow | -72.35M |
| FCF Per Share | -1.11 |
Margins
Gross margin is 100%, with operating and profit margins of -6280.83% and -6090.94%.
| Gross Margin | 100% |
| Operating Margin | -6280.83% |
| Pretax Margin | -6088.4% |
| Profit Margin | -6090.94% |
| EBITDA Margin | -3928.42% |
| EBIT Margin | -6280.83% |
| FCF Margin | -4716.36% |
Dividends & Yields
LYRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LYRA is $1.25, which is 941.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.25 |
| Price Target Difference | 941.7% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -10.9 |
| Piotroski F-Score | 3 |